Cyclic peptide nanocarriers overcome drug resistance and improve targeted colon cancer treatment
Cyclic peptide-based nanocarriers (liposomes, niosomes, nanosponges) improve drug delivery, tumor penetration, and drug resistance in colon cancer by combining cyclic peptide anticancer activity with nanocarrier controlled release.
Quick Facts
What This Study Found
Cyclic peptides: structural stability, enhanced bioavailability, target specificity. Nanocarrier types: liposomes, niosomes, nanosponges, nanopolymers. Benefits: targeted delivery, controlled release, drug resistance overcome. Sources: plant, marine, microbial.
Key Numbers
How They Did This
Comprehensive narrative review of cyclic peptide sources, mechanisms, therapeutic applications, and nanocarrier integration for colon cancer.
Why This Research Matters
Colon cancer is a leading cause of cancer death, and drug resistance limits treatment. Cyclic peptide nanocarriers address both challenges: natural anticancer activity plus smart delivery to overcome resistance.
The Bigger Picture
Cyclic peptides bridge natural products and nanotechnology, combining evolution-refined anticancer activity with engineered delivery precision for one of the most common and deadly cancers.
What This Study Doesn't Tell Us
Review of primarily preclinical data. Clinical translation of cyclic peptide nanocarriers is early. Manufacturing complexity and cost unknown. In vivo efficacy data limited.
Questions This Raises
- ?Which cyclic peptide nanocarrier is closest to clinical trials?
- ?Can these systems be adapted for other GI cancers?
- ?How do cyclic peptide nanocarriers compare to antibody-drug conjugates?
Trust & Context
- Key Stat:
- Overcome drug resistance Cyclic peptide nanocarriers combine natural anticancer activity with targeted delivery to address colon cancer drug resistance—a key clinical challenge
- Evidence Grade:
- Narrative review of preclinical advances. Promising technology platform but limited clinical data.
- Study Age:
- Published in 2025.
- Original Title:
- Unlocking the Therapeutic Potential of Cyclic Peptide-Based Nanocarriers for Enhanced Colon Cancer Treatment.
- Published In:
- The protein journal, 44(6), 691-716 (2025)
- Authors:
- Souresh, Vedhapriya, Srikayalsamyukktha, M, Harini, M, Saravanan, Yudhesh, Saravanakumar, Rupachandra
- Database ID:
- RPEP-13658
Evidence Hierarchy
Frequently Asked Questions
What are cyclic peptides?
Cyclic peptides are small proteins that form a ring structure, making them more stable than linear peptides. Many found in nature (from plants, sea creatures, and microbes) have powerful anticancer properties. Their ring shape also makes them better at entering cells and resisting breakdown in the body.
How do nanocarriers improve colon cancer treatment?
Nanocarriers are tiny particles that protect drugs during transport through the body and release them specifically at the tumor site. By attaching cyclic peptides to nanocarriers, researchers achieve double benefit: the nanocarrier delivers the drug precisely to the colon tumor, while the cyclic peptide provides its own anticancer effect and helps overcome drug resistance.
Read More on RethinkPeptides
Related articles coming soon.
Cite This Study
https://rethinkpeptides.com/research/RPEP-13658APA
Souresh, Vedhapriya; Srikayalsamyukktha, M; Harini, M; Saravanan, Yudhesh; Saravanakumar, Rupachandra. (2025). Unlocking the Therapeutic Potential of Cyclic Peptide-Based Nanocarriers for Enhanced Colon Cancer Treatment.. The protein journal, 44(6), 691-716. https://doi.org/10.1007/s10930-025-10289-2
MLA
Souresh, Vedhapriya, et al. "Unlocking the Therapeutic Potential of Cyclic Peptide-Based Nanocarriers for Enhanced Colon Cancer Treatment.." The protein journal, 2025. https://doi.org/10.1007/s10930-025-10289-2
RethinkPeptides
RethinkPeptides Research Database. "Unlocking the Therapeutic Potential of Cyclic Peptide-Based ..." RPEP-13658. Retrieved from https://rethinkpeptides.com/research/souresh-2025-unlocking-the-therapeutic-potential
Access the Original Study
Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.
This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.